有机化学人才网 | 最新人才 | 最新职位 | 技术交易 | 药物合成 |
   
全站搜索: |
  您当前位置:网站首页 >> 药物合成路线图解
 

药物详细合成路线

Name Amprenavir;KVX-478;141W94;VX-478;Prozei;Agenerase
Chemical Name 4-Amino-N-[2(R)-hydroxy-4-phenyl-3(S)-[tetrahydrofuran-3(S)-yloxycarbonylamino]butyl]-N-isobutylbenzenesulfonamide
      (1S,2R)-3-[N-(4-Aminophenylsulfonyl)-N-ispropylamino]-1-benzyl-2-hydroxypropylcarbamic acid (3S)-tetrahydro-3-furanyl ester
CAS 161814-49-9
Related CAS
Formula C25H35N3O6S
Structure
Formula Weight 505.6382
Stage 上市-1999
Company Vertex (Originator), GlaxoSmithKline (Licensee), Kissei (Licensee)
Activity/Mechanism AIDS Medicines, Anti-HIV Agents, ANTIINFECTIVE THERAPY, HIV Protease Inhibitors
Syn. Route 3
Route 1
the reaction of the chiral epoxide (i) with isobutylamine (ii) in refluxing ethanol gives the secondary amine (iii), which is protected with benzyl chloroformate (iv) and tea, yielding the dicarbamate (v). selective deprotection of (v) with dry hcl in ethyl acetate affords the primary amine (vi), which is treated with 3(s)-tetrahydrofuryl n-succinimidinyl carbonate (vii) (prepared by condensation of tetrahydrofuran-3(s)-ol (viii) with phosgene and n-hydroxysuccinimide (ix)) and diea in acetonitrile to provide the corresponding carbamate (x). the deprotection of (x) by hydrogenation with h2 over pd/c in ethanol gives the secondary amine (xi), which is condensed with 4-nitrophenylsulfonyl chloride (xii) by means of nahco3 in dichloromethane/water to yield the sulfonamide (xiii). finally, the nitro group of (xiii) is reduced with h2 over pd/c in ethyl acetate to afford the target compound.
List of intermediates No.
[5-[3-benzoyl-2,4-dioxo-5-vinyl-3,4-dihydro-1(2h)-pyrimidinyl]-3-(benzoyloxy)tetrahydro-2-furanyl]methyl benzoate (iv)
(3r,4s)-4-[(1s)-2,2-dimethylcyclopropyl]-1-(4-methoxyphenyl)-3-[(triisopropylsilyl)oxy]-2-azetidinone (ix)
(e)-7-phenyl-2-heptenoic acid (ii)
6-chloro-3-oxo-2-oxabicyclo[3.2.1]octane-8-carbaldehyde (xii)
1-[(2r,3s,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydro-2-furanyl]-5-vinyl-2,4(1h,3h)-pyrimidinedione (i)
(vii)
2-(1,2,6,7-tetrahydro-8h-indeno[5,4-b]furan-8-ylidene)-1-ethanamine; 2-(1,2,6,7-tetrahydro-8h-indeno[5,4-b]furan-8-ylidene)ethylamine (iii)
n-[2-(1,2,6,7-tetrahydro-8h-indeno[5,4-b]furan-8-ylidene)ethyl]propanamide (v)
2-(1,6,7,8-tetrahydro-2h-indeno[5,4-b]furan-8-yl)-1-ethanamine; 2-(1,6,7,8-tetrahydro-2h-indeno[5,4-b]furan-8-yl)ethylamine (vi)
n-[2-(1,6,7,8-tetrahydro-2h-indeno[5,4-b]furan-8-yl)ethyl]propanamide (viii)
(4s)-1-(4-methoxybenzyl)-4-methyl-3,4-dihydro-2(1h)-pyridinone (x)
(1s,5s,6r)-7,7-dichloro-2-(4-methoxybenzyl)-5-methyl-2-azabicyclo[4.1.0]heptan-3-one (xi)
(1s,5s,6r,7r)-7-chloro-5-methyl-2-azabicyclo[4.1.0]heptan-3-one (xiii)
Reference 1:
    tung, r.d.; murcko, m.a.; bhisetti, g.r. (vertex pharmaceuticals inc.); sulfonamide inhibitors of hiv-aspartyl protease. ep 0659181; ep 0885887; jp 1996501299; us 5585397; wo 9405639 .

Route 2
reaction of the chiral epoxide (i) with isobutylamine (ii) in refluxing ethanol gives the secondary amine (iii), which is condensed with 4-nitrophenylsulfonyl chloride (iv) and tea in hot toluene to yield the sulfonamide (v). deprotection of (v) with hcl hot toluene/water affords the primary amine (vi), which is condensed with imidazole-1-carboxylic acid 3(s)-tetrahydrofuryl ester (vii) [prepared by reaction of tetrahydrofuran-3(s)-ol (viii) with carbonyldiimidazole (cdi) in ethyl acetate] to provide the corresponding carbamate (ix). finally, the nitro group of (ix) is reduced with h2 over pd/c in ethyl acetate to afford the target compound.
List of intermediates No.
(e)-7-phenyl-2-heptenoic acid (ii)
6-chloro-3-oxo-2-oxabicyclo[3.2.1]octane-8-carbaldehyde (iv)
1-[(2r,3s,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydro-2-furanyl]-5-vinyl-2,4(1h,3h)-pyrimidinedione (i)
2-(1,2,6,7-tetrahydro-8h-indeno[5,4-b]furan-8-ylidene)-1-ethanamine; 2-(1,2,6,7-tetrahydro-8h-indeno[5,4-b]furan-8-ylidene)ethylamine (iii)
n-[2-(1,6,7,8-tetrahydro-2h-indeno[5,4-b]furan-8-yl)ethyl]propanamide (viii)
(1s,5s,6r,7r)-7-chloro-5-methyl-2-azabicyclo[4.1.0]heptan-3-one (ix)
methyl (2s)-2-[(tert-butoxycarbonyl)amino]-5-hexenoate (v)
methyl (2s)-2-[(tert-butoxycarbonyl)amino]-6-(diethoxyboryl)hexanoate (vi)
methyl (2s)-2-[(tert-butoxycarbonyl)amino]-6-[(1s,2s,6r,8s)-2,9,9-trimethyl-3,5-dioxa-4-boratricyclo[6.1.1.0~2,6~]dec-4-yl]hexanoate (vii)
Reference 1:
    deininger, d.d.; ocallaghan, j.; mcguie, s.; singh, h.; robertson, m.s.; rodgers, k.; tung, r.d.; al-farhan, e.; rout, s.j. (glaxo group ltd.); process for the synthesis of hiv protease inhibitors. wo 9948885 .

Route 3
the reaction of n,n-dibenzyl-l-alaninal (i) with nitromethane, catalyzed by the chiral ammonium salt (ii) and kf in thf gives the chiral nitroalcohol (iii), which is reduced with nicl2 and nabh4 to yield the aminoalcohol (iv). the condensation of (iv) with isobutyraldehyde (v) affords the schiff base (vi), which is reduced with nabh4 to provide the secondary amine (vii). the reaction of (vii) with 4-nitrobenzenesulfonyl chloride (viii) and tea in dichloromethane furnishes the sulfonamide (ix), which is deprotected by hydrogenation with h2 over pd/c in methanol, giving the diamino compound (x). finally, this compound is condensed with 3(s)-tetrahydrofuryl (n-oxysuccinimidyl) carbonate (xi) by means of tea in dichloromethane to afford the target carbamate.
List of intermediates No.
tert-butyl [(3r,4s)-1-benzyl-4-(trifluoromethyl)pyrrolidinyl]methylcarbamate (v)
6-chloro-3-oxo-2-oxabicyclo[3.2.1]octane-8-carbaldehyde (viii)
ethyl (2s)-2-amino-4-((2r)-2-[[(2s)-2-(2-[6-[amino(imino)methyl]-1-ethyl-1h-indol-2-yl]ethyl)pyrrolidinyl]carbonyl]pyrrolidinyl)-4-oxobutanoate (i)
2-nitroethyl acetate (vii)
(xi)
benzyl (2s)-5-[(benzoyloxy)(methyl)amino]-2-[((2s)-2,6-bis{[2,3-bis(acetyloxy)benzoyl]amino}hexanoyl)amino]-5-oxopentanoate (ii)
(2s)-5-[(benzoyloxy)(methyl)amino]-2-[((2s)-2,6-bis{[2,3-bis(acetyloxy)benzoyl]amino}hexanoyl)amino]-5-oxopentanoic acid (iii)
(7s,11s,12r,13s,14r,15r,16r,17s,18s)-2,15,17-trihydroxy-11-methoxy-3,7,12,14,16,18-hexamethyl-6,23,27,29-tetraoxo-8,30-dioxa-24-azatetracyclo[23.3.1.1~4,7~.0~5,28~]triaconta-1(28),2,4,9,19,21,25-heptaen-13-yl acetate (iv)
(7s,11s,12r,13s,14r,15r,16r,17s,18s)-2,15,17,32-tetrahydroxy-11-methoxy-3,7,12,14,16,18-hexamethyl-6,23,37-trioxo-8,27,38-trioxa-24,34-diazahexacyclo[23.11.1.1~4,7~.0~5,36~.0~26,35~.0~28,33~]octatriaconta-1(36),2,4,9,19,21,25,28,30,32,34-undecaen-13-yl acetate (vi)
n-isobutyl piperazine (ix)
(7s,11s,12r,13s,14r,15r,16r,17s,18s)-32-{[tert-butyl(dimethyl)silyl]oxy}-2,15,17-trihydroxy-11-methoxy-3,7,12,14,16,18-hexamethyl-6,23,37-trioxo-8,27,38-trioxa-24,34-diazahexacyclo[23.11.1.1~4,7~.0~5,36~.0~26,35~.0~28,33~]octatriaconta-1(36),2,4,9,19,21,25,28,30,32,34-undecaen-13-yl acetate (x)
Reference 1:
    corey, e.j.; zhang, f.-y.; re- and si-face-selective nitroaldol reactions catalyzed by a rigid chiral quaternary ammonium salt: a highly stereoselective synthesis of the hiv protease inhibitor amprenavir (vertex 478). angew chem. int ed engl 1999, 38, 13-14, 1931.

来源:药化网

作者:药化小编

摘要:本文合成路线介绍的是药物中文名安普那韦;英文名Amprenavir;KVX-478;141W94;VX-478;Prozei;Agenerase;CAS[161814-49-9]

 
推荐VIP企业
无锡景耀生物科技有限公司
杭州卢普生物科技有限公司
宁波赛伦化工有限公司
苏州昊赛生物科技有限公司
北京嘉盛扬医药科技有限公司
上海泽涵生物医药科技有限公司
河北固安三利化工公司
郑州凯普瑞生物技术有限公司
上海药谷药业有限公司
兰州康寓信生物科技有限公司
湖北朗昕生化药业有限公司
武汉福鑫化工有限公司
嘉兴市英南化工有限公司
苏州迪飞医药科技有限公司
北京富安凯科技有限公司
上海盛中医药化工有限公司
连云港天和化学有限公司
南京晨瑞医药科技有限公司
南京苏如化工有限公司
常州瑞盛化工有限公司
热门文章
科迪华旗下喹禾灵除草剂产品线被
国光股份募集资金投资项目变更实
杨森在欧洲申请优特克单抗用于治
BMS 白血病药物组合 Spr
辉瑞与默克宣布终止癌症药物 B
增加至7000万!国光股份子公
hVIVO 启动通用流感疫苗
民族骄傲!氰烯菌酯再获国家科学
农药领域的行政许可事项相互之间
暂停?不存在的!2019年将全
诺华镰状细胞病药物 Criza
全力整改!广安利尔草铵膦生产线
葛兰素史克积极寻求处于研发初期
多个植保农药类项目拟提名201
市场行情走低,库存持续消化
EMA 批准氟替卡松用于儿童哮
安进骨质疏松症药物 Eveni
葛兰素史克时隔 4 年拟重返肿
河南地区醋酸价格
山东地区醋酸价格下调
 友情链接
有机化学人才网  
首页 | 广告服务 | 建站服务 | 关于我们 | 联系我们 | 版权声明